Rolf Richter

3.2k total citations
149 papers, 2.2k citations indexed

About

Rolf Richter is a scholar working on Reproductive Medicine, Surgery and Oncology. According to data from OpenAlex, Rolf Richter has authored 149 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Reproductive Medicine, 45 papers in Surgery and 33 papers in Oncology. Recurrent topics in Rolf Richter's work include Ovarian cancer diagnosis and treatment (82 papers), Intraperitoneal and Appendiceal Malignancies (30 papers) and Endometrial and Cervical Cancer Treatments (24 papers). Rolf Richter is often cited by papers focused on Ovarian cancer diagnosis and treatment (82 papers), Intraperitoneal and Appendiceal Malignancies (30 papers) and Endometrial and Cervical Cancer Treatments (24 papers). Rolf Richter collaborates with scholars based in Germany, Austria and Belgium. Rolf Richter's co-authors include Jalid Sehouli, Renate L. Bergmann, Karl E. Bergmann, Elena Ioana Braicu, Joachim W. Dudenhausen, Christina Fotopoulou, Radoslav Chekerov, Hannah Woopen, Rüdiger von Kries and J. W. Dudenhausen and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Rolf Richter

144 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rolf Richter Germany	25	894	692	592	451	419	149	2.2k
Geneviève Plu‐Bureau France	34	750 0.8×	440 0.6×	199 0.3×	372 0.8×	356 0.8×	120	3.9k
Lars‐Åke Mattsson Sweden	25	420 0.5×	473 0.7×	313 0.5×	472 1.0×	259 0.6×	52	2.2k
Simone Garzon Italy	28	1.4k 1.6×	1.4k 2.1×	355 0.6×	142 0.3×	237 0.6×	143	2.6k
Martin Davidson United States	11	1.8k 2.0×	609 0.9×	1.1k 1.8×	921 2.0×	109 0.3×	23	2.9k
William M. Hague Australia	39	662 0.7×	2.8k 4.1×	1.3k 2.3×	310 0.7×	1.4k 3.2×	125	4.7k
Michael P. Hopkins United States	27	462 0.5×	799 1.2×	508 0.9×	397 0.9×	225 0.5×	69	1.8k
Anna K.L. Reyners Netherlands	29	218 0.2×	250 0.4×	352 0.6×	1.0k 2.3×	199 0.5×	129	2.5k
Nuri Danışman Türkiye	28	217 0.2×	1.6k 2.3×	342 0.6×	206 0.5×	1.2k 2.9×	205	2.7k
Jakob Lauritsen Denmark	25	429 0.5×	274 0.4×	888 1.5×	124 0.3×	384 0.9×	96	1.9k
Velja Mijatovic Netherlands	31	1.3k 1.4×	1.1k 1.6×	283 0.5×	227 0.5×	218 0.5×	147	2.7k

Countries citing papers authored by Rolf Richter

Since Specialization

Citations

This map shows the geographic impact of Rolf Richter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Richter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Richter more than expected).

Fields of papers citing papers by Rolf Richter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolf Richter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Richter. The network helps show where Rolf Richter may publish in the future.

Co-authorship network of co-authors of Rolf Richter

This figure shows the co-authorship network connecting the top 25 collaborators of Rolf Richter. A scholar is included among the top collaborators of Rolf Richter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolf Richter. Rolf Richter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nasser, Sara, Rolf Richter, Jacek Grabowski, et al.. (2024). Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study. Cancers. 16(3). 622–622. 3 indexed citations

Zickler, Daniel, Juliane Bolbrinker, Rolf Richter, et al.. (2023). Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis. Cancer Chemotherapy and Pharmacology. 91(4). 325–330. 5 indexed citations

Richter, Rolf, et al.. (2023). Sexuality as a prognostic factor: Results of an individual participant data NOGGO-meta-analysis of 1,041 recurrent ovarian cancer patients before starting chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). e24128–e24128. 1 indexed citations

Chekerov, Radoslav, Klaus Pietzner, Ulrich Canzler, et al.. (2023). Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ). Journal of Cancer Research and Clinical Oncology. 149(10). 7637–7649. 2 indexed citations

Sehouli, Jalid, Rolf Richter, Wolfgang Henrich, et al.. (2022). Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. International Journal of Gynecological Cancer. 32(6). 716–723. 1 indexed citations

Sehouli, Jalid, Alexander Mustea, Maren Keller, et al.. (2021). Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. Cancers. 13(19). 4739–4739. 4 indexed citations

Trillsch, Fabian, Sven� Mahner, Bastian Czogalla, et al.. (2021). Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. Journal of Gynecologic Oncology. 32(3). e37–e37. 8 indexed citations

Grabowski, Jacek, et al.. (2018). Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients. Anticancer Research. 38(10). 5853–5858. 10 indexed citations

Sehouli, Jalid, et al.. (2018). Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer. Anticancer Research. 38(8). 4865–4870. 6 indexed citations

10.

Woopen, Hannah, Pauline Wimberger, Alexander Mustea, et al.. (2017). Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Annals of Oncology. 28. v340–v341. 3 indexed citations

11.

Muallem, Mustafa Zelal, Klaus Pietzner, Rolf Richter, et al.. (2016). Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.. PubMed. 36(8). 4227–32. 27 indexed citations

12.

Woopen, Hannah, et al.. (2016). Elderly ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). European Journal of Cancer. 60. 101–106. 8 indexed citations

13.

Braicu, Elena Ioana, et al.. (2015). Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer. Annals of Surgical Oncology. 22(8). 2729–2737. 40 indexed citations

14.

Sehouli, Jalid, Christina Fotopoulou, Rolf Richter, et al.. (2015). Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. European Journal of Cancer. 51(7). 825–832. 8 indexed citations

15.

Braicu, Elena Ioana, Toon Van Gorp, Mani Nassir, et al.. (2014). Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium. Journal of Ovarian Research. 7(1). 49–49. 17 indexed citations

16.

Braicu, Elena Ioana, Rolf Richter, Dan Cacsire Castillo‐Tong, et al.. (2014). HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy. 7. 1563–1563. 17 indexed citations

17.

Braicu, Elena Ioana, Christina Fotopoulou, Radoslav Chekerov, et al.. (2013). Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO–AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine. 61(3). 755–758. 15 indexed citations

18.

Richter, Rolf, et al.. (2000). Rechtsextremismus und Antifaschismus : historische und aktuelle Dimensionen. Dietz eBooks. 2 indexed citations

19.

Schindler, C, et al.. (1987). [Central neurotoxic side effects following cisplatin therapy].. PubMed. 109(1). 60–3. 3 indexed citations

20.

Kielholz, P, et al.. (1972). HASCHISCH UND FAHRVERHALTEN. EINE EXPERIMENTELLE UNTERSUCHUNG.. DMW - Deutsche Medizinische Wochenschrift. 97(20). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact